Friday, July 10, 2026

pharma · Ependymoma, Medulloblastoma · chronically occluded coronary artery

Ishita Pharma -

ISTA Pharma is a pharma organization headquartered in GB. Primary therapeutic focus areas include Ependymoma, Medulloblastoma, chronically occluded coronary artery, Hereditary Angioedema, Acute kidney injury, knee osteoa

Mumbai, IN HQ
3 Employees
EMA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Employees
3
Programs
8
Drugs
19
Patents
0
Clinical program

RCAPHM19_0374

Phase 3 · small molecule · Traumatism

RCAPHM19_0374 for Traumatism is a Phase 3 program (small_molecule) at ISTA Pharma Limited with 1 ClinicalTrials.gov record(s).

← All ISTA Pharma Limited projects Phase 3 small molecule active

Internal code RCAPHM19_0374

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ISTA Pharma Limited
Phase
Phase 3
Modality
small_molecule
Indication
Traumatism
Status
active
Trials
1